SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer
2026-05-19 · SynDevRx, Inc. · original syndevrx.com ↗
SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2− mBC patients with PI3K pathway alterations. May 19, 2026 /EINPresswire.com/ — SynDevRx, Inc., a clinical-stage oncology company, today announced it will share interim data from the ongoing AMELIA™-1 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights the potential of evexomostat, a first-in-class MetAP2 inhibitor, to address angiogenic and metabolic drivers of resistance in PI3K/AKT pathway altered HR+/HER2− metastatic breast cancer in combination with capivasertib or alpelisib.
The release as fetched from its publisher. syndevrx.com ↗